Current Clinical Trials
In December 2015, the phase I clinical trial was successfully completed: The results exceeded the expectations of MetrioPharm's team significantly. Even with six times exceeding the therapeutic dose no adverse reactions to MP1032 were observed in the probands. In May 2016, the implementation of the phase IIa has started (First Patient, First Dose on 24-May-16).
Phase IIa: MP1032 for the treatment of moderate-to-severe
chronic plaque psoriasis
The phase IIa trial is conducted in Germany as a randomized, double-blind, placebo-controlled exploratory pilot study with twice-daily oral dosing. Psoriasis patients aged 18 to 65 years will receive a six-week treatment with placebo or MP1032. An enrolment of a total of 44 male and female participants with chronic plaque psoriasis is planned in this clinical trial. Participants are divided into two groups of 22 participants each. Primary endpoints of the study include pharmacokinetics and safety and tolerability of multiple doses of MP1032 over six weeks in patients. Preliminary evidence of effectiveness is examined as a secondary endpoint.